Lipoxins and new lipid mediators in the resolution of inflammation

Current Opinion in Pharmacology

Volumn 6, Issue 4, 2006, Pages 414-420

  Schwab, Jan M ^a   Serhan, Charles N ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANANDAMIDE; ANTIINFLAMMATORY AGENT; AUTACOID; CANNABINOID DERIVATIVE; CYCLOPENTENONE; DELTA15 PROSTAGLANDIN J2; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INDOMETACIN; ISOPROSTANE DERIVATIVE; LIPOXIN; LIPOXIN A; LIPOXIN A DERIVATIVE; NEUROPROTECTIVE AGENT; OMEGA 3 FATTY ACID; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN E2; PROTECTIN D1; PROTECTIN DERIVATIVE; RESOLVIN D DERIVATIVE; RESOLVIN D1; RESOLVIN D2; RESOLVIN D3; RESOLVIN D4; RESOLVIN E DERIVATIVE; RESOLVIN E1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; DIGESTIVE SYSTEM INFLAMMATION; DISEASE CONTROL; DRUG MECHANISM; DRUG STRUCTURE; EYE INFLAMMATION; HOMEOSTASIS; HUMAN; INFLAMMATORY DISEASE; LIPID ANALYSIS; MEDIATOR; MOUTH INFLAMMATION; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; SKIN INFLAMMATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONIC ACIDS; ASPIRIN; DISEASE MODELS, ANIMAL; DOCOSAHEXAENOIC ACIDS; EICOSAPENTAENOIC ACID; HUMANS; INFLAMMATION; LIPID METABOLISM; LIPOXINS; SIGNAL TRANSDUCTION;

EID: 33745728329     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2006.02.006     Document Type: Review

References (33)

1. Serhan C.N., and Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6 (2005) 1191-1197
2. Serhan C.N. The lipoxins and the aspirin triggered lipoxins. Prostaglandins Leukot Essent Fatty Acids 73 (2005) 3-4
3. Majno G., and Joris I. Cells, Tissues, and Disease. Principles of general pathology (1996), Blackwell Science, Cambridge
4. In: Gallin J.I., Snyderman R., Fearon D.T., Haynes B.F., and Nathan C. (Eds). Inflammation: Basic Principles and Clinical Correlates. edn 3 (1999), Lippincott Williams & Wilkins, Philadelphia
5. Helgadottir A., Manolescu A., Thorleifsson G., Gretarsdottir S., Jonsdottir H., Thorsteinsdottir U., Samani N.J., Gudmundsson G., Grant S.F., Thorgeirsson G., et al. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet 36 (2004) 233-239
6. Karp C.L., Flick L.M., Park K.W., Softic S., Greer T.M., Keledjian R., Yang R., Uddin J., Guggino W.B., Atabani S.F., et al. Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. Nat Immunol 5 (2004) 388-392. Important link between LX dysfunction and chronic inflammation.
7. Bannenberg G.L., Aliberti J., Hong S., Sher A., and Serhan C. Exogenous pathogen and plant 15-lipoxygenase initiate endogenous lipoxin A4 biosynthesis. J Exp Med 199 (2004) 515-523
8. Vance R.E., Hong S., Gronert K., Serhan C.N., and Mekalanos J.J. The opportunistic pathogen Pseudomonas aeruginosa carries a secretable arachidonate 15-lipoxygenase. Proc Natl Acad Sci USA 101 (2004) 2135-2139
9. Serhan C.N., Clish C.B., Brannon J., Colgan S.P., Chiang N., and Gronert K. Novel functional sets of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp Med 192 (2000) 1197-1204
10. Serhan C.N., Hong S., Gronert K., Colgan S.P., Devchand P.R., Mirick G., et al. Resolvins: a family of bioactive products of omega-3 fatty acidtransformation circuits initiated by aspirin treatment that counter pro- inflammation signals. J Exp Med 196 (2002) 1025-1037
11. Hong S., Gronert K., Devchand P., Moussignac R.-L., and Serhan C.N. Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 278 (2003) 14677-14687
12. Gilroy D.W., Lawrence T., Perretti M., and Rossi A.G. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 3 (2004) 401-416. An outstanding review: a must-read review of the literature illustrating the potential for resolution-based drug targets.
13. De Petrocellis L., Cascio M.G., and Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141 (2004) 765-774
14. Serhan C.N., Maddox J.F., Petasis N.A., Akritopoulou-Zanze I., Papayianni A., Brady H.R., Colgan S.P., and Madara J.L. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 34 (1995) 14609-14615
15. Gilroy D.W., and Perretti M. Aspirin and steroids: new mechanistic findings and avenues for drug discovery. Curr Opin Pharmacol 5 (2005) 405-411
16. Nathan C. Points of control in inflammation. Nature 420 (2002) 846-852
17. Libby P. Atherosclerosis: the new view. Sci Am 286 (2002) 46-55
18. Samuelsson B., Dahlen S.E., Lindgren J.A., Rouzer C.A., and Serhan C.N. Leukotrienes and lipoxins: structures, biosynthesis, and biological effects. Science 237 (1987) 1171-1176
19. Levy B.D., Clish C.B., Schmidt B., Gronert K., and Serhan C.N. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2 (2001) 612-619
20. GISSI-Prevenzione Investigators: Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet 1999. 354:447-455.
21. Arita M., Bianchini F., Aliberti J., Sher A., Chiang N., Hong S., Yang R., Petasis N.A., and Serhan C.N. Stereochemical assignment, anti-inflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 (2005) 713-722
22. Bannenberg G.L., Chiang N., Ariel A., Arita M., Tjonahen E., Gotlinger K.H., Hong S., and Serhan C.N. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 174 (2005) 4345-4355. Study defining resolution of inflammation in quantitative terms. This study was the first to provide tools to determine resolution time frames as a prerequisite for the search for new resolution agonists such as ATLs, Rvs and PDs.
23. Vane J.R. Adventures and excursions in bioassay: the stepping stones to prostacyclin. Les Prix Nobel: Nobel Prizes, Presentations Biographies and Lectures (1982), Almqvist & Wiksell, Stockholm 181-206
24. Clària J., and Serhan C.N. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci USA 92 (1995) 9475-9479
25. Devchand P.R., Arita M., Hong S., Bannenberg G., Moussignac R.-L., Gronert K., et al. Human ALX receptor regulates neutrophil recruitment in transgenic mice: roles in inflammation and host-defense. FASEB J 17 (2003) 652-659
26. Hasturk H., Kantarci A., Ohira T., Arita M., Ebrahimi N., Chiang N., et al. RvE1 protects from local inflammation and osteoclast-mediated bone destruction in periodontitis. FASEB J 20 (2006) 401-403
27. Arita M., Yoshida M., Hong S., Tjonahen E., Glickman J.N., Petasis N.A., Blumberg R.S., and Serhan C.N. Resolvin E1, a novel endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against TNBS-induced colitis. Proc Natl Acad Sci USA 102 (2005) 7671-7676
28. Marcheselli V.L., Hong S., Lukiw W.J., Hua Tian X., Gronert K., Musto A., Hardy M., Gimenez J.M., Chiang N., Serhan C.N., and Bazan N.G. Novel docosanoids inhibit brain ischemia-reperfusion-mediated leukocyte infiltration and pro-inflammatory gene expression. J Biol Chem 278 (2003) 43807-43817
29. Serhan C.N., Gotlinger K., Hong S., Lu Y., Siegelman J., Baer T., Yang R., Colgan S.P., and Petasis N.A. Anti-inflammatory actions of neuroprotectin D1/protectin D1 and its natural stereoisomers: assignments of dihydroxy-containing docosatrienes. J Immunol 176 (2006) 1848-1859
30. Mukherjee P.K., Marcheselli V.L., Serhan C.N., and Bazan N.G. Neuroprotectin D1: a docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci USA 101 (2004) 8491-8496. This study reports the protection upon oxidative stress in the central nervous system. NPD1 application upregulates the anti-apoptotic Bcl-2 and Bcl-x(L) in response to NPD1 treatment, whereas the pro-apoptotic Bax and Bad are downregulated resulting in reduced caspase-3 cleavage.
31. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., Serhan C.N., and Bazan N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 115 (2005) 2774-2783. Study involving human brain samples indicating a role for NPD1 in silencing the pro-inflammatory response following amyloid-β peptide challenge while upregulating anti-apoptotic genes.
32. Ariel A., Li P.L., Wang W., Tang W.X., Fredman G., Hong S., Gotlinger K.H., and Serhan C.N. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 280 (2005) 43079-43086
33. Gronert K., Maheshwari N., Khan N., Hassan I.R., and Dunn M. Laniado. Schwartzman M. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 280 (2005) 15267-15278. This study provides the first evidence that resolution agonists promote tissue remodelling and wound healing in the cornea.